SGLT2 inhibitors on Blue MedicareRx Premier (S2893-003)
Jardiance, Farxiga and the other SGLT2 inhibitors, for diabetes, heart failure and kidney disease, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Connecticut + 3 more
- Premium
- $238.60/month
- Deductible
- None
3 of 6 SGLT2 inhibitors are covered on this plan. None require prior authorization.
3 aren't on the formulary, including Invokana and Steglatro.
- $30.00Tier 3
- $30.00Tier 3
- $1.00Tier 1
Not on the formulary
Invokana, Steglatro, Inpefa
Patient cost for a 30-day supply at a preferred retail pharmacy. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.